Dalcetrapib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Dalcetrapib
- Molecular weight
- 389.61
- Structure (SMILES)
- CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1
- dalcetrapib
- Dalcetrapib
- dalcetrapib (RO4607381)
- Dalcetrapib (RO4607381)
- dalcetrapib [INN]
- DALCETRAPIB [MI]
- DALCETRAPIB [USAN]
- Dalcetrapib [WHO-DD]
- dalcetrapib inn
- dalcetrapib mi
- dalcetrapib usan
- dalcetrapib who dd
- jtt 705
- JTT-705
- JTT-705 300mg
- JTT-705 600mg
- JTT-705 900mg
- propanethioic acid 2 methyl s 2 1 2 ethylbutyl cyclohexyl carbonyl amino phenyl ester
- PROPANETHIOIC ACID, 2-METHYL-, S-(2-(((1-(2-ETHYLBUTYL)CYCLOHEXYL)CARBONYL)AMINO)PHENYL) ESTER
- ro 4607381
- RO-4607381
- ro4607381
- RO4607381
- CAS registry numbers
- 211513-37-0
- ChEMBL ID
- CHEMBL313006
- InChIKey
- YZQLWPMZQVHJED-UHFFFAOYSA-N
- PubChem compound IDs
- 6918540
- FDA ingredient codes (UNII)
- 3D050LIQ3H
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- dalcetrapib
- Type
- Synthetic organic
- Drug name stem
- -cetrapib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cholesteryl ester transfer protein
- Gene symbol
- CETP
- Protein identifier
- P11597
- Median affinity
- 5.39
- Affinity units
- pIC50
- Mechanism
- Cholesteryl ester transfer protein inhibitor
- Action type
- Inhibitor
- Target
- Cholesteryl ester transfer protein
- Protein identifier
- P11597
Open Targets mechanisms
- Mechanism
- Cholesteryl ester transfer protein inhibitor
- Action type
- Inhibitor
- Target
- Cholesteryl ester transfer protein
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Peripheral Arterial Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004265
- Subject identifier
- D058729
- Condition
- Acute Coronary Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005672
- Subject identifier
- D054058
- Condition
- Dyslipidemias
- Highest recorded phase
- 3
- Condition identifier
- HP:0003119
- Subject identifier
- D050171
- Condition
- Hyperlipidemias
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0021187
- Subject identifier
- D006949
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition
- Lipid Metabolism Disorders
- Highest recorded phase
- 2
- Condition identifier
- Orphanet:309005
- Subject identifier
- D052439
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001645
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004265
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005672
- Highest recorded phase
- 3
- Condition identifier
- HP_0003119
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001336
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005010
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005542
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0021187
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- Condition identifier
- Orphanet_309005
- Highest recorded phase
- 2
- NCT00353522
- NCT00400439
- NCT00655473
- NCT00655538
- NCT00658515
- NCT01323153
- NCT01516541
- NCT00688558
- NCT00689442
- NCT00697203
- NCT00688896
- NCT01059682
- NCT02525939
- NCT05918861
- NCT04676867
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 46.17
- Calculated partition coefficient (ALogP)
- 6.68
- Calculated partition coefficient (XLogP)
- 7.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 8
- Heavy atoms
- 27
- Molecular formula
- C23H35NO2S
- Monoisotopic mass
- 389.23885053
- Natural product
- Yes
- Recorded assays
- 185
- Active assays
- 14
- Confirmatory
- Screening
- Anticholesteremic Agents
Related records
Trials (18)
- A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
- A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
- A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
- A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
- A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
- A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
- A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
- A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
- A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
- A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers
- A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
- Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
- Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
- Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
- Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
- Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
- Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
- Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
In development for (8)
- Acute coronary syndrome Phase 3
- Cardiovascular disorder Phase 3
- Coronary artery disorder Phase 3
- COVID-19 Phase 2
- Familial hyperlipidemia Phase 3
- Hyperlipidemia Phase 2
- Inherited lipid metabolism disorder Phase 2
- Peripheral arterial disease Phase 3
Targets (1)
- CETP Cholesteryl ester transfer protein inhibitor